• X4 Pharmaceuticals will host a virtual Investor Day on Oct. 29, 2026, from 10:00 a.m. to 12:00 p.m. ET.
• Agenda centers on mavorixafor in chronic neutropenia, including an update on the Phase 3 4WARD trial status.
• Management plans to outline a Phase 2 trial combining mavorixafor with G-CSF to assess G-CSF dose reduction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610090700PRIMZONEFULLFEED9842636) on October 09, 2026, and is solely responsible for the information contained therein.